Zebrafish screen identifies novel compound with selective toxicity against leukemia.
暂无分享,去创建一个
Archana Agarwal | J Kimble Frazer | Matthew Sigman | E. Manos | David A Jones | M. Deininger | N. Trede | R. Miles | C. Guidos | G. Spangrude | A. Eiring | M. Müschen | M. Sigman | Gerald J Spangrude | Markus Müschen | Michael Deininger | W. Heaton | A. Agarwal | T. Perova | Deepa Joshi | Nikolaus S Trede | Rodney R Miles | Cynthia J Guidos | Priya Choudhry | Bertrand Montpellier | James E. Cox | Suzanne Ridges | Will L Heaton | Henry Choi | Anna Eiring | Lance Batchelor | Elizabeth J Manos | Hossein Sofla | Ali Sanati | Seth Welborn | James E Cox | Kaveri Balan | Tatiana Perova | Radia Johnson | Radia M. Johnson | James E. Cox | Lance A. Batchelor | J. Frazer | D. Joshi | Bertrand Montpellier | David A. Jones | P. Choudhry | Suzanne Ridges | Henry Choi | Hossein Sofla | A. Sanati | Seth Welborn | K. Balan
[1] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[2] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.
[3] Michael J. Parsons,et al. Protein Kinase B Regulates T Lymphocyte Survival, Nuclear Factor κb Activation, and Bcl-XL Levels in Vivo , 2000, The Journal of experimental medicine.
[4] L. Zon,et al. A Chemical Genetic Screen for Cell Cycle Inhibitors in Zebrafish Embryos , 2006, Chemical biology & drug design.
[5] A. Ruggeri,et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells , 2003, Leukemia.
[6] R. Peterson,et al. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation , 2009, Nature chemical biology.
[7] E. Lai. Notch Cleavage: Nicastrin Helps Presenilin Make the Final Cut , 2002, Current Biology.
[8] M. DePamphilis,et al. Regulating the licensing of DNA replication origins in metazoa. , 2006, Current opinion in cell biology.
[9] R. Peterson,et al. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression , 2007, Development.
[10] L. Zon,et al. In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] William A Weiss,et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.
[12] D. V. van Aalten,et al. PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.
[13] J. Baselga,et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.
[14] F. Quelle,et al. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. , 2001, Blood.
[15] Marc Adler,et al. Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1* , 2005, Journal of Biological Chemistry.
[16] K. Sachs,et al. Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data , 2005, Science.
[17] A. Ferrando,et al. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia , 2008, Cell cycle.
[18] G Pruneri,et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. , 2000, Cancer research.
[19] P. Majumder,et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. , 2009, Blood.
[20] G. Basso,et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells , 2011, Leukemia.
[21] Randall W King,et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant , 2005, Nature chemical biology.
[22] A. Ferrando,et al. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. , 2000, Seminars in hematology.
[23] S. Armstrong,et al. Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Zon,et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis , 2007, Nature.
[25] J. Kaye,et al. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[27] References , 1971 .
[28] C. Higgins,et al. Multiple molecular mechanisms for multidrug resistance transporters , 2007, Nature.
[29] K. Lam,et al. Fas Apoptosis Inhibitory Molecule Regulates T Cell Receptor-mediated Apoptosis of Thymocytes by Modulating Akt Activation and Nur77 Expression* , 2010, The Journal of Biological Chemistry.
[30] M. Juntilla,et al. Critical roles of the PI3K/Akt signaling pathway in T cell development. , 2008, Immunology letters.
[31] David M Langenau,et al. Myc-Induced T Cell Leukemia in Transgenic Zebrafish , 2003, Science.
[32] Paul Workman,et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.
[33] Francis Collins,et al. Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia , 1996, Cell.
[34] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[35] Ching-Hon Pui,et al. Acute lymphoblastic leukemia. , 2004, The New England journal of medicine.
[36] A. Gedman,et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. , 2009, Blood.
[37] D E Koshland. The cell cycle. , 1989, Science.
[38] D. Neuberg,et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia , 2011, The Journal of experimental medicine.
[39] Andrew W. Murray,et al. The Cell Cycle , 1989 .
[40] N. Trede,et al. Immunology and zebrafish: spawning new models of human disease. , 2008, Developmental and comparative immunology.
[41] J. McCubrey,et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. , 2009, Cancer research.
[42] Jing Chen,et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.
[43] L. Chin,et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. , 2009, Blood.
[44] Govind Bhagat,et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.
[45] S. Tripp,et al. Heritable T Cell Malignancy Models Established in a Zebrafish Phenotypic Screen , 2009, Leukemia.
[46] Adam Smith,et al. Screening for drug discovery: The leading question , 2002, Nature.
[47] R. Gelber,et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Charles Y. Lin,et al. DHODH modulates transcriptional elongation in the neural crest and melanoma , 2011, Nature.
[49] K. McManus,et al. The relationship between histone H3 phosphorylation and acetylation throughout the mammalian cell cycle. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.